With the intent of NK cell activation as a strategy to improve the immunotherapy of DLBCL, authors studied NKp44, one of NCR receptors, which its activation improve its role against malignant cells [110]. The gene discussed is NCR2; the disease is diffuse large B-cell lymphoma.